aTyr Pharma, Inc. (LIFE)
| Market Cap | 44.00M |
| Revenue (ttm) | 8.55M |
| Net Income (ttm) | -17.27M |
| Shares Out | 9.65M |
| EPS (ttm) | -2.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $4.27 |
| Previous Close | $4.32 |
| Change ($) | -0.05 |
| Change (%) | -1.16% |
| Day's Open | 4.26 |
| Day's Range | 4.22 - 4.48 |
| Day's Volume | 351,900 |
| 52-Week Range | 2.13 - 8.33 |
These seven names have shown important insider trading signals after their rallies, meaning some insiders are taking profits in these stocks. The post 7 Stocks With Important Insider Trading S...
aTyr Pharma Inc (NASDAQ: LIFE) has initiated two discovery programs from its tRNA synthetase platform that will investigate the functionality of selected fragments of Alanyl-tRNA Synthetase (A...
Advancement of selected AARS and DARS fragments primarily targeting cancer
SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biologi...
Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biologi...
Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2020 Results - Earnings Call Transcript
C omplete s e nrollment of ATYR1923 c linical t rial in patients with COVID-19 s evere r espiratory c omplications . Topline data is expected at turn of calendar year.
Peer-reviewed paper supports aTyr's antibody program .
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biologi...
Although penny stocks come with an added element of risk, investing in the right stocks could set you up for massive gains in the future. Here are the best penny stocks to buy right now.
Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 i...
Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months.
These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential ap...
SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immu...
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines bas...
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2020 Results - Earnings Call Transcript
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 5.48% and -52.75%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT
Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan. Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 ...
Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer.
Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen in...
Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S. Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S.
Atyr Pharma (LIFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Andreas Halvorsen (Trades, Portfolio)’s Viking Global Investors bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q1 2020 Results - Earnings Call Transcript
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 238.89% and 83.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immu...
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and 69.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2019 Results - Earnings Call Transcript
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program
SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immu...
Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states
aTyr Pharma (LIFE) soars on a collaboration and license agreement with Kyorin Pharmaceutical for lead candidate.
Shares of the thinly traded nano-cap biotech aTyr Pharma Inc (NASDAQ: LIFE) were advancing strongly Monday on above-average volume.
aTyr eligible to receive up to $175 million in total payments, including $8 million upfront, plus tiered sales royalties
ATYR1923 safe and well tolerated in initial 15 randomized patients with pulmonary sarcoidosis
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2019 Results - Earnings Call Transcript
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2019 Results - Earnings Call Transcript
aTyr Pharma's (LIFE) CEO Sanjay Shukla on Q1 2019 Results - Earnings Call Transcript
Atyr Pharma (LIFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2018 Results - Earnings Call Transcript
About LIFE
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the d... [Read more...]
| Industry Biotechnology | IPO Date May 7, 2015 |
| CEO Sanjay Shukla | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol LIFE |
Analyst Forecasts
According to 3 analysts, the average rating for aTyr Pharma stock is "Buy." The 12-month stock price forecast is 13.33, which is an increase of 212.18% from the latest price.